GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculatur...